Travere Therapeutics Inc
TVTXHealthcare|Biotechnology|USA
$56.60
-1.88 (-3.22%)
Upcoming Data Readouts (4)
Mar 2027
Est. completion
P4Proteinuria
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121n=20
Mar 2027
Est. completion
P2Focal Segmental Glomerulosclerosis
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986n=67
Aug 2027
Est. completion
P3Homocystinuria
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085n=70
Dec 2027
Est. completion
P2Immunoglobulin A Nephropathy
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
NCT04663204n=24
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P1P2
Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
NCT03406611Aug 2023
P3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850